Drug Profile
Efepoetin alfa - Genexine Biologics
Alternative Names: Ephepoetin Alpha; EPO-hFC; EPO-hybrid Fc; EPO-hyFc; Erythropoietin biobetter - Genexine; GC-1113; GX-E2; GX-E4; HyPoietin; Long-acting EPO; Recombinant erythropoietin long-acting - Genexine/GC BiopharmaLatest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator Genexine
- Developer Genexine; PT Kalbe Genexine Biologics
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Anaemia